← Back to all signals
RESEARCH PAPER ANALYSIS

Regular Metronome, Fractal Metronome, and Music for Parkinson Gait.

In a small case-control study of medicated Parkinson patients, a fractal metronome improved stride-time fluctuation structure while listening to music increased gait velocity, stride length, and arm swing compared with no cue or a regular metronome.

PMID41989783
JournalJAMA network open
Publication Date2026-04-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

In a small case-control study of medicated Parkinson patients, a fractal metronome improved stride-time fluctuation structure while listening to music increased gait velocity, stride length, and arm swing compared with no cue or a regular metronome.

WHY IT MATTERS

Research significance

This paper supports nonpharmacologic auditory cueing (music or fractal metronome) as clinically useful rehabilitation strategies and highlights stride-time DFA as a sensitive outcome measure for gait interventions, but it offers limited direct insights for molecular or drug-target discovery.

ABSTRACT

Source abstract

IMPORTANCE: Persons with Parkinson walk slowly, with short steps, reduced arm swing, and altered stride variability. Walking to a metronome or music may increase velocity, stride length, and cadence, yet few studies have directly compared the efficacy of these techniques. OBJECTIVE: To determine the optimal auditory cue to improve Parkinson gait. DESIGN, SETTING, AND PARTICIPANTS: This case-control study was conducted among persons with Parkinson disease (using medication) and healthy older adult controls at University of Florida Applied Neuromechanics laboratory in 2017. Changes in gait in participants with Parkinson disease and controls were compared with walking with no cue: walking to a regular metronome, walking to a fractal metronome, and walking to music. Condition order was randomized. Cueing frequency was set to natural cadence. Post hoc analyses restricted to participants with Parkinson disease were performed in 2026. EXPOSURES: Auditory cueing with a regular metronome, fractal metronome, or music while walking. MAIN OUTCOMES AND MEASURES: Outcomes of interest were stride time detrended fluctuation analysis (DFA), velocity, stride length, and arm swing velocity. Spatiotemporal gait measures and DFA of stride time were compared using repeated measures multivariate analysis of variance. RESULTS: Analyses included 15 participants with Parkinson disease (mean [SD] age, 69 [6] years; 11 [73%] male; mean [SD] Hoehn and Yahr Parkinson disease stage. 2.3 [0.6]; mean [SD] age of onset, 63 [7] years) and 15 controls (mean [SD] age, 69 [5] years; 11 [73%] male). Stride time DFA was increased during the fractal metronome condition (α = 0.200; SE, 0.024; P < .001) vs no cue, the regular metronome (α = 0.320; SE, 0.032; P < .001), and music (α = 0.219; SE, 0.030; P < .001); worsened with the regular metronome vs no cue (α = -0.120; SE, 0.037; P = .003); and was not statistically different during music vs no cue (α = -0.019; SE, 0.031; P = .54). Music was associated with increased velocity (mean [SE] change, 0.041 [0.015] m/s; P = .01), stride length (mean [SE] change, 0.047 [0.013] m; P = .001), and arm swing velocity (mean [SE] change, 27.10 [7.33] °/s; P = .001) compared with no cue; velocity (mean [SE] change, 0.030 [0.011] m/s; P = .03), stride length (mean [SE] change, 0.034 [0.009] m; P = .002), and arm swing velocity (mean [SE] change, 34.7 [8.5] °g/s; P = .001) compared with the regular metronome; and increased stride length (mean [SE] change, 0.028 [0.009] m; P = .01) and arm swing velocity (mean [SE] change, 37.52 [7.89] °/s; P < .001) compared with the fractal metronome. Analyses restricted to participants with Parkinson disease found similar trends, with reduced levels of significance due to the smaller sample. CONCLUSIONS AND RELEVANCE: In this case-control study, walking to the fractal metronome was associated with improved stride time fluctuations compared with the regular metronome or music. Walking to music was associated with improved velocity, stride length, and arm swing velocity compared with either metronome condition.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic